Live price temporarily unavailable.
Immunocore Holdings (IMCR) is a Health Care company. Latest news and coverage below.
| FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $36.5M | $174.4M | $249.4M | $310.2M | $400.0M |
| Growth (year over year) | — | +377.9% | +43.1% | +24.4% | +29.0% |
| Gross profit | $36.5M | $173.3M | $248.4M | $307.5M | $394.9M |
| Gross margin | 100.0% | 99.4% | 99.6% | 99.1% | 98.7% |
| Operating income | −$174.6M | −$51.7M | −$59.6M | −$70.5M | −$45.4M |
| Operating margin | −478.5% | −29.7% | −23.9% | −22.7% | −11.3% |
| Net income | −$180.0M | −$52.5M | −$55.3M | −$51.1M | −$35.5M |
| Net margin | −493.4% | −30.1% | −22.2% | −16.5% | −8.9% |
| EPS (diluted) | −$4.24 | −$1.15 | −$1.13 | −$1.02 | −$0.71 |
| Balance sheet | |||||
| Cash and equivalents | $321.1M | $402.5M | $442.6M | $455.7M | $467.7M |
| Total assets | — | $526.8M | $597.0M | $1.01B | $1.07B |
| Total liabilities | — | $187.9M | $228.2M | $648.8M | $686.2M |
| Shareholders' equity | $233.7M | $338.9M | $368.8M | $360.7M | $381.0M |
| Cash flow | |||||
| Operating cash flow | −$143.1M | −$49.2M | $2.94M | $26.1M | −$10.7M |
| Capital expenditure | $1.39M | $2.20M | $5.42M | $5.17M | $4.34M |
| Free cash flow | −$144.5M | −$51.4M | −$2.48M | $20.9M | −$15.1M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $80.2M | $84.1M | $93.9M | $98.0M | $103.7M | $104.5M | $106.7M | $115.9M |
| Growth (year over year) | +23.7% | +19.8% | +33.2% | +29.9% | +29.2% | +24.3% | +13.6% | +18.3% |
| Gross profit | $79.8M | $83.7M | $93.0M | $96.9M | $103.2M | $101.8M | $106.2M | $114.8M |
| Gross margin | 99.4% | 99.6% | 99.1% | 98.9% | 99.5% | 97.4% | 99.6% | 99.1% |
| Operating income | −$8.50M | −$19.5M | −$3.62M | −$14.9M | −$7.17M | −$19.7M | $7.28M | −$3.00M |
| Operating margin | −10.6% | −23.1% | −3.9% | −15.2% | −6.9% | −18.8% | 6.8% | −2.6% |
| Net income | $8.74M | −$23.8M | $5.02M | −$10.3M | −$177.0K | −$30.1M | $13.0M | −$808.0K |
| Net margin | 10.9% | −28.3% | 5.4% | −10.5% | −0.2% | −28.8% | 12.2% | −0.7% |
| EPS (diluted) | $0.17 | −$0.47 | $0.10 | −$0.20 | $0.00 | −$0.61 | $0.25 | −$0.02 |
| Balance sheet | ||||||||
| Cash and equivalents | $537.8M | $455.7M | $476.8M | $487.9M | $498.4M | $467.7M | $452.7M | $484.9M |
| Total assets | $1.08B | $1.01B | $1.03B | $1.08B | $1.10B | $1.07B | $1.07B | $1.12B |
| Total liabilities | $706.8M | $648.8M | $649.5M | $693.9M | $705.9M | $686.2M | $678.4M | $699.6M |
| Long-term debt | $438.7M | — | — | — | — | — | — | — |
| Shareholders' equity | $377.8M | $360.7M | $378.5M | $388.5M | $396.6M | $381.0M | $393.7M | $419.8M |
| Cash flow | ||||||||
| Operating cash flow | $21.1M | −$14.0M | $435.0K | $26.0M | −$4.46M | −$32.7M | −$13.8M | $15.9M |
| Capital expenditure | $828.0K | $3.58M | $298.0K | $414.0K | $748.0K | $2.88M | $1.78M | $786.0K |
| Free cash flow | $20.3M | −$17.5M | $137.0K | $25.6M | −$5.20M | −$35.5M | −$15.6M | $15.1M |
From Immunocore Holdings's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Immunocore Holdings in our feed yet.